FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.486,32 +3.402,43 (+6,18%)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Dopo ore:
| Chiusura precedente | 0,1711 |
| Aperto | 0,1815 |
| Denaro | 0,1821 x 100 |
| Lettera | 0,1854 x 200 |
| Min-Max giorno | 0,1780 - 0,1870 |
| Intervallo di 52 settimane | 0,1200 - 3,3125 |
| Volume | |
| Media Volume | 2.290.367 |
| Capitalizzazione | 17,532M |
| Beta (5 anni mensile) | 2,23 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -6,8500 |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 3,48 |
GlobeNewswireTonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Topline Results Expected Early November 2023 Tianeptine, the Active Ingredient in TNX-601 ER, is Not Associated with Sexual Dysfunction or Weight Gain Which are Treatment-Limiting Side Effects of Many Traditional Antidepressants Tianeptine Acts by Directly Restoring Neuroplasticity and Neurogenesis and Limiting the Effects of Oxidative Stress in the Brain CHATHAM, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical compan
- GlobeNewswire
Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City. Investors interest
- GlobeNewswire
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe
CHATHAM, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical, Tonix Pharmaceuticals, will present at the World Vaccine Congress Europe on Wednesday, October 18, 2023, at 2:45 p.m. CEST in Barcelona, Spain. A copy of the Company’s presentation will be available under the Scientific
